Production and Characterization of Monoclonal Antibodies Against Complexes of the NKT Cell Ligand Alpha-galactosylceramide Bound to Mouse CD1d

Overview

Journal J Immunol Methods

Publisher Elsevier

Specialties Allergy & Immunology
Pathology

Date 2007 Apr 20

PMID 17442335

Citations 36

Authors

Karl O A Yu

Jin S Im

Petr A Illarionov

Rachel M Ndonye

Amy R Howell

Gurdyal S Besra

Steven A Porcelli

Affiliations

Soon will be listed here.

Abstract

The alpha-galactosylceramide (alpha-GalCer) known as KRN7000 remains the best studied ligand of the lipid-binding MHC class I-like protein CD1d. The KRN7000:CD1d complex is highly recognized by invariant natural killer T (iNKT) cells, an evolutionarily conserved subset of T lymphocytes that express an unusual semi-invariant T cell antigen receptor, and mediate a variety of proinflammatory and immunoregulatory functions. To facilitate the study of glycolipid antigen presentation to iNKT cells by CD1d, we undertook the production of mouse monoclonal antibodies (mAbs) specific for complexes of KRN7000 bound to mouse CD1d (mCD1d) proteins. Three such monoclonal antibodies were isolated that bound only to mCD1d proteins that were loaded with KRN7000 or closely-related forms of alpha-GalCer. These mAbs showed no reactivity with mCD1d proteins that were not loaded with alpha-GalCer, nor did they bind to complexes formed by loading mCD1d with the self-glycolipid and putative iNKT cell ligand isoglobotrihexosylceramide. These complex-specific monoclonal antibodies allow the direct detection and monitoring of complexes formed by the binding of KRN7000 and other alpha-GalCer analogues to mCD1d. The availability of these mAbs should facilitate a wide range of studies on the biology and potential clinical applications of CD1d-restricted iNKT cells.

Citing Articles

Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.

Sharma Kharkwal S, Johndrow C, Veerapen N, Kharkwal H, Saavedra-Avila N, Carreno L Cancer Res. 2021; 81(7):1788-1801.

PMID: 33483371 PMC: 8137529. DOI: 10.1158/0008-5472.CAN-20-2219.

Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.

Clark K, Yau J, Bloom A, Wang J, Venzon D, Suzuki M Front Immunol. 2019; 10:2355.

PMID: 31649670 PMC: 6794452. DOI: 10.3389/fimmu.2019.02355.

Control of CD1d-restricted antigen presentation and inflammation by sphingomyelin.

Melum E, Jiang X, Baker K, Macedo M, Fritsch J, Dowds C Nat Immunol. 2019; 20(12):1644-1655.

PMID: 31636468 PMC: 7249499. DOI: 10.1038/s41590-019-0504-0.

Structural basis of NKT cell inhibition using the T-cell receptor-blocking anti-CD1d antibody 1B1.

Ying G, Wang J, Mallevaey T, Van Calenbergh S, Zajonc D J Biol Chem. 2019; 294(35):12947-12956.

PMID: 31296659 PMC: 6721955. DOI: 10.1074/jbc.RA119.009403.

Development of a High-Quality ELISA Method for Dinotefuran Based on a Novel and Newly-Designed Antigen.

Zhao F, Liu J, Luo J Molecules. 2019; 24(13).

PMID: 31269647 PMC: 6651010. DOI: 10.3390/molecules24132426.

References

Mattner J, DeBord K, Ismail N, Goff R, Cantu 3rd C, Zhou D . Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature. 2005; 434(7032):525-9. DOI: 10.1038/nature03408. View

Kinjo Y, Wu D, Kim G, Xing G, Poles M, Ho D . Recognition of bacterial glycosphingolipids by natural killer T cells. Nature. 2005; 434(7032):520-5. DOI: 10.1038/nature03407. View

Yu K, Im J, Molano A, Dutronc Y, Illarionov P, Forestier C . Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci U S A. 2005; 102(9):3383-8. PMC: 552918. DOI: 10.1073/pnas.0407488102. View

Behar S, Podrebarac T, Roy C, Wang C, Brenner M . Diverse TCRs recognize murine CD1. J Immunol. 1999; 162(1):161-7. View

Spada F, Koezuka Y, Porcelli S . CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med. 1998; 188(8):1529-34. PMC: 2213414. DOI: 10.1084/jem.188.8.1529. View

Brossay L, Tangri S, Bix M, Cardell S, Locksley R, Kronenberg M . Mouse CD1-autoreactive T cells have diverse patterns of reactivity to CD1+ targets. J Immunol. 1998; 160(8):3681-8. View

Roark J, Park S, Jayawardena J, Kavita U, Shannon M, Bendelac A . CD1.1 expression by mouse antigen-presenting cells and marginal zone B cells. J Immunol. 1998; 160(7):3121-7. View

Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K . CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 1997; 278(5343):1626-9. DOI: 10.1126/science.278.5343.1626. View

Brossay L, Jullien D, Cardell S, Sydora B, Burdin N, Modlin R . Mouse CD1 is mainly expressed on hemopoietic-derived cells. J Immunol. 1997; 159(3):1216-24. View

10.

Porgador A, Yewdell J, Deng Y, Bennink J, Germain R . Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity. 1997; 6(6):715-26. DOI: 10.1016/s1074-7613(00)80447-1. View

11.

Smiley S, Kaplan M, Grusby M . Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells. Science. 1997; 275(5302):977-9. DOI: 10.1126/science.275.5302.977. View

12.

Murphy D, Lo D, Rath S, Brinster R, Flavell R, Slanetz A . A novel MHC class II epitope expressed in thymic medulla but not cortex. Nature. 1989; 338(6218):765-8. DOI: 10.1038/338765a0. View

13.

LACHMANN P, Strangeways L, Vyakarnam A, Evan G . Raising antibodies by coupling peptides to PPD and immunizing BCG-sensitized animals. Ciba Found Symp. 1986; 119:25-57. DOI: 10.1002/9780470513286.ch3. View

14.

Galfre G, Milstein C . Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol. 1981; 73(Pt B):3-46. DOI: 10.1016/0076-6879(81)73054-4. View

15.

Goff R, Gao Y, Mattner J, Zhou D, Yin N, Cantu 3rd C . Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc. 2004; 126(42):13602-3. DOI: 10.1021/ja045385q. View

16.

Wallner F, Chen L, Moliner A, Jondal M, Elofsson M . Loading of the antigen-presenting protein CD1d with synthetic glycolipids. Chembiochem. 2004; 5(4):437-44. DOI: 10.1002/cbic.200300655. View

17.

Im J, Yu K, Illarionov P, LeClair K, Storey J, Kennedy M . Direct measurement of antigen binding properties of CD1 proteins using fluorescent lipid probes. J Biol Chem. 2003; 279(1):299-310. DOI: 10.1074/jbc.M308803200. View

18.

Stanic A, Shashidharamurthy R, Bezbradica J, Matsuki N, Yoshimura Y, Miyake S . Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected]. J Immunol. 2003; 171(9):4539-51. DOI: 10.4049/jimmunol.171.9.4539. View

19.

Itano A, McSorley S, Reinhardt R, Ehst B, Ingulli E, Rudensky A . Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity. 2003; 19(1):47-57. DOI: 10.1016/s1074-7613(03)00175-4. View

20.

Miyamoto K, Miyake S, Yamamura T . A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature. 2001; 413(6855):531-4. DOI: 10.1038/35097097. View